Vaccines (May 2021)

Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines

  • Francesco Nicoli,
  • Salvatore Pacifico,
  • Eleonora Gallerani,
  • Erika Marzola,
  • Valentina Albanese,
  • Valentina Finessi,
  • Sian Llewellyn-Lacey,
  • David A. Price,
  • Victor Appay,
  • Peggy Marconi,
  • Remo Guerrini,
  • Antonella Caputo,
  • Riccardo Gavioli

DOI
https://doi.org/10.3390/vaccines9050526
Journal volume & issue
Vol. 9, no. 5
p. 526

Abstract

Read online

Peptide vaccines incorporating B- and T-cell epitopes have shown promise in the context of various cancers and infections. These vaccines are relatively simple to manufacture, but more immunogenic formulations are considered a priority. We developed tetrabranched derivatives for this purpose based on a novel peptide welding technology (PWT). PWTs provide molecular scaffolds for the efficient synthesis of ultrapure peptide dendrimers, which allow the delivery of multiple ligands within a single macromolecular structure. Peptide vaccines incorporating T-cell epitopes derived from melanoma and B-cell epitopes derived from human immunodeficiency virus, synthesized using this approach, elicited primary immune responses in vitro and in vivo. Subcutaneous administration of the B-cell epitope-based vaccines also elicited more potent humoral responses than subcutaneous administration of the corresponding peptides alone. Highly immunogenic peptide epitope-based vaccines can therefore be generated quickly and easily using a novel PWT.

Keywords